HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings In Brief

This article was originally published in The Rose Sheet

Executive Summary

Elizabeth Arden: Prevage anti-aging treatment launch will be supported with print ads in 21 magazines over the next eight weeks, in addition to radio spots and Internet banners, company announces during Nov. 3 Q1 call. Prevage will be distributed in department and specialty stores including Saks Fifth Avenue, Nordstrom, Bloomingdale's, Henri Bendel and Bergdorf Goodman. The firm unveiled the line in September (1"The Rose Sheet" Aug. 15, 2005, p. 4). Arden's net sales increased 7.2% to $227.4 mil. for the first quarter (ended Sept. 30). Net income was $1.9 mil., excluding stock compensation expense, versus $4.8 mil. in the same period last year, due in part to weak consumer spending in Western Europe, Arden said. The firm has lowered full fiscal 2006 guidance, with sales expected to increase 6.5%-8% to $980 mil.-$995 mil., versus earlier expectations of $1 bil. - $1.02 bil. Earnings per diluted share for the year are anticipated to increase to $1.33-$1.39, excluding stock compensation expense...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts